Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 2823671, 14 pages
https://doi.org/10.1155/2017/2823671
Review Article

Antidiabetic Effect of Brain-Derived Neurotrophic Factor and Its Association with Inflammation in Type 2 Diabetes Mellitus

1Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland
2Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
3Faculty of Rehabilitation, University of Physical Education, Warsaw, Poland

Correspondence should be addressed to Dagmara Mirowska-Guzel; lp.ude.muw@aksworimd

Received 24 April 2017; Revised 12 July 2017; Accepted 22 August 2017; Published 14 September 2017

Academic Editor: Bernard Portha

Copyright © 2017 Ceren Eyileten et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 32, Supplement 1, pp. S62–S67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Lontchi-Yimagou, E. Sobngwi, T. E. Matsha, and A. P. Kengne, “Diabetes mellitus and inflammation,” Current Diabetes Reports, vol. 13, no. 3, pp. 435–444, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. P. Mattson, S. Maudsley, and B. Martin, “BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders,” Trends in Neurosciences, vol. 27, pp. 589–594, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Cohen-Cory, A. H. Kidane, N. J. Shirkey, and S. Marshak, “Brain-derived neurotrophic factor and the development of structural neuronal connectivity,” Developmental Neurobiology, vol. 70, pp. 271–288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Mirowska-Guzel, “The role of neurotrophic factors in the pathology and treatment of multiple sclerosis,” Immunopharmacology and Immunotoxicology, vol. 31, no. 1, pp. 32–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Gezen-Ak, E. Dursun, H. Hanağası et al., “BDNF, TNFα, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment,” Journal of Alzheimer's Disease, vol. 37, no. 1, pp. 185–195, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. A. H. Nagahara and M. H. Tuszynski, “Potential therapeutic uses of BDNF in neurological and psychiatric disorders,” Nature Reviews Drug Discovery, vol. 10, no. 3, pp. 209–219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Manni, V. Nikolova, D. Vyagova, G. N. Chaldakov, and L. Aloe, “Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes,” International Journal of Cardiology, vol. 102, pp. 169–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Suwa, H. Kishimoto, Y. Nofuji et al., “Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus,” Metabolism, vol. 55, pp. 852–857, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. R. Tonra, M. Ono, X. Liu et al., “Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr (db)/lepr(db) mice,” Diabetes, vol. 48, pp. 588–594, 1999. View at Google Scholar
  11. M. Yamanaka, Y. Itakura, A. Tsuchida, T. Nakagawa, and M. Taiji, “Brain-derived neurotrophic factor (BDNF) prevents the development of diabetes in prediabetic mice,” Biomedical Research, vol. 29, no. 3, pp. 147–153, 2008. View at Google Scholar
  12. L. F. Reichardt, “Neurotrophin-regulated signalling pathways,” Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences, vol. 361, pp. 1545–1564, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. V. Chao, R. Rajagopal, and F. S. Lee, “Neurotrophin signalling in health and disease,” Clinical Science (London), vol. 110, pp. 167–173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Farinas, “Neurotrophin actions during the development of the peripheral nervous system,” Microscopy Research and Technique, vol. 45, pp. 233–242, 1999. View at Publisher · View at Google Scholar
  15. A. K. McAllister, “Neurotrophins and neuronal differentiation in the central nervous system,” Cellular and Molecular Life Sciences, vol. 58, pp. 1054–1060, 2001. View at Publisher · View at Google Scholar
  16. S. Cohen and M. E. Greenberg, “Communication between the synapse and the nucleus in neuronal development, plasticity, and disease,” Annual Review of Cell and Developmental Biology, vol. 24, pp. 183–209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Rodriguez-Tebar, G. Dechant, and Y. A. Barde, “Binding of brain-derived neurotrophic factor to the nerve growth factor receptor,” Neuron, vol. 4, pp. 487–492, 1990. View at Google Scholar
  18. R. Klein, V. Nanduri, S. A. Jing et al., “The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3,” Cell, vol. 66, pp. 395–403, 1991. View at Google Scholar
  19. K. Bartkowska, K. Turlejski, and R. L. Djavadian, “Neurotrophins and their receptors in early development of the mammalian nervous system,” Acta Neurobiologiae Experimentalis (Wars), vol. 70, pp. 454–467, 2010. View at Google Scholar
  20. R. Lee, P. Kermani, K. K. Teng, and B. L. Hempstead, “Regulation of cell survival by secreted proneurotrophins,” Science, vol. 294, pp. 1945–1948, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. W. J. Friedman, “Neurotrophins induce death of hippocampal neurons via the p75 receptor,” Journal of Neuroscience, vol. 20, pp. 6340–6346, 2000. View at Google Scholar
  22. M. M. Hofer and Y. A. Barde, “Brain-derived neurotrophic factor prevents neuronal death in vivo,” Nature, vol. 331, pp. 261-262, 1988. View at Publisher · View at Google Scholar
  23. B. Knüsel, J. W. Winslow, A. Rosenthal et al., “Promotion of central cholinergic and dopaminergic neuron differentiation by brainderived neurotrophic factor but not neurotrophin 3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, pp. 961–965, 1991. View at Google Scholar
  24. K. K. Cowansage, J. E. LeDoux, and M. H. Monfils, “Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity,” Current Molecular Pharmacology, vol. 3, pp. 12–29, 2010. View at Google Scholar
  25. R. Klein, D. Conway, L. F. Parada, and M. Barbacid, “The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain,” Cell, vol. 61, no. 4, pp. 647–656, 1990. View at Google Scholar
  26. T. Numakawa, S. Suzuki, E. Kumamaru, N. Adachi, M. Richards, and H. Kunugi, “BDNF function and intracellular signaling in neurons,” Histology and Histopathology, vol. 25, pp. 237–258, 2010. View at Publisher · View at Google Scholar
  27. K. Ohira, K. J. Homma, H. Hirai, S. Nakamura, and M. Hayashi, “TrkB-T1 regulates the RhoA signaling and actin cytoskeleton in glioma cells,” Biochemical and Biophysical Research Communications, vol. 342, no. 3, pp. 867–874, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. T. A. Yacoubian and D. C. Lo, “Truncated and full-length TrkB receptors regulate distinct modes of dendritic growth,” Nature Neuroscience, vol. 3, no. 4, pp. 342–349, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. R. H. Fryer, D. R. Kaplan, and L. F. Kromer, “Truncated trkB receptors on nonneuronal cells inhibit BDNF-induced neurite outgrowth in vitro,” Experimental Neurology, vol. 148, no. 2, pp. 616–627, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Shibayama and H. Koizumi, “Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues,” American Journal of Pathology, vol. 148, no. 6, pp. 1807–1818, 1996. View at Google Scholar
  31. N. Takei, K. Furukawa, O. Hanyu, H. Sone, and H. Nawa, “A possible link between BDNF and mTOR in control of food intake,” Frontiers in Psychology, vol. 5, p. 1093, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. E. E. Noble, C. J. Billington, C. M. Kotz, and C. Wang, “The lighter side of BDNF,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 300, no. 5, pp. R1053–R1069, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Vanevski and B. Xu, “Molecular and neural bases underlying roles of BDNF in the control of body weight,” Frontiers in Neuroscience, vol. 7, p. 37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. S. M. Rothman, K. J. Griffioen, R. Wan, and M. P. Mattson, “Brain-derived neurotrophic factor as a regulator of systemic and brain energy metabolism and cardiovascular health,” Annals of the New York Academy of Sciences, vol. 1264, pp. 49–63, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Xu, E. H. Goulding, K. Zang et al., “Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor,” Nature Neuroscience, vol. 6, no. 7, pp. 736–742, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Bariohay, J. Roux, C. Tardivel, J. Trouslard, A. Jean, and B. Lebrun, “Brain-derived neurotrophic factor/tropomyosin-related kinase receptor type B signaling is a downstream effector of the brainstem melanocortin system in food intake control,” Endocrinology, vol. 150, no. 6, pp. 2646–2653, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. M. J. Donovan, M. I. Lin, P. Wiegn et al., “Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization,” Development, vol. 127, no. 21, pp. 4531–4540, 2000. View at Google Scholar
  38. D. Cassiman, C. Denef, V. J. Desmet, and T. Roskams, “Human and rat hepatic stellate cells express neurotrophins and neurotrophin receptors,” Hepatology, vol. 33, pp. 148–158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Kerschensteiner, E. Gallmeier, L. Behrens et al., “Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?” The Journal of Experimental Medicine, vol. 189, no. 5, pp. 865–870, 1999. View at Google Scholar
  40. F. Karege, G. Bondolfi, N. Gervasoni, M. Schwald, J. M. Aubry, and G. Bertschy, “Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity,” Biological Psychiatry, vol. 57, pp. 1068–1072, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Yamamoto and M. E. Gurney, “Human platelets contain brain-derived neurotrophic factor,” Journal of Neuroscience, vol. 10, pp. 3469–3478, 1990. View at Google Scholar
  42. H. Fujimura, C. A. Altar, R. Chen et al., “Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation,” Thrombosis and Haemostasis, vol. 87, pp. 728–734, 2002. View at Google Scholar
  43. P. A. Lapchak and F. Hefti, “BDNF and NGF treatment in lesioned rats: effects on cholinergic function and weight gain,” Neuroreport, vol. 3, pp. 405–408, 1992. View at Google Scholar
  44. M. A. Pelleymounter, M. J. Cullen, and C. L. Wellman, “Characteristics of BDNF-induced weight loss,” Experimental Neurology, vol. 131, pp. 229–238, 1995. View at Google Scholar
  45. M. Ono, Y. Itakura, T. Nonomura et al., “Intermittent administration of brain-derived neurotrophic factor ameliorates glucose metabolism in obese diabetic mice,” Metabolism, vol. 49, pp. 129–133, 2000. View at Google Scholar
  46. T. Nonomura, A. Tsuchida, M. Ono-Kishino, T. Nakagawa, M. Taiji, and H. Noguchi, “Brain-derived neurotrophic factor regulates energy expenditure through the central nervous system in obese diabetic mice,” International Journal of Experimental Diabetes Research, vol. 2, pp. 201–209, 2001. View at Google Scholar
  47. O. Hanyu, K. Yamatani, T. Ikarashi et al., “Brain-derived neurotrophic factor modulates glucagon secretion from pancreatic alpha cells: its contribution to glucose metabolism,” Diabetes, Obesity and Metabolism, vol. 5, pp. 27–37, 2003. View at Google Scholar
  48. G. S. Yeo, C. C. Connie Hung, J. Rochford et al., “A de novo mutation affecting human TrkB associated with severe obesity and developmental delay,” Nature Neuroscience, vol. 7, no. 11, pp. 1187–1189, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Gray, G. S. Yeo, J. J. Cox et al., “Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene,” Diabetes, vol. 55, no. 12, pp. 3366–3371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Karczewska-Kupczewska, I. Kowalska, A. Nikołajuk et al., “Circulating brain-derived neurotrophic factor concentration is downregulated by intralipid/heparin infusion or high-fat meal in young healthy male subjects,” Diabetes Care, vol. 35, no. 2, pp. 358–362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Eyileten, M. Zaremba, P. K. Janicki et al., “Serum brain-derived neurotrophic factor is related to platelet reactivity but not to genetic polymorphisms within BDNF encoding gene in patients with type 2 diabetes,” Medical Science Monitor, vol. 22, pp. 69–76, 2016. View at Google Scholar
  52. B. Boyuk, S. Degirmencioglu, H. Atalay et al., “Relationship between levels of brain-derived neurotrophic factor and metabolic parameters in patients with type 2 diabetes mellitus,” Journal of Diabetes Research, vol. 2014, Article ID 978143, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. K. S. Krabbe, A. R. Nielsen, R. Krogh-Madsen et al., “Brain-derived neurotrophic factor (BDNF) and type 2 diabetes,” Diabetologia, vol. 50, pp. 431–438, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. B. Li, N. Lang, and Z. F. Cheng, “Serum levels of brain-derived neurotrophic factor are associated with diabetes risk, complications, and obesity: a cohort study from Chinese patients with type 2 diabetes,” Molecular Neurobiology, vol. 53, no. 8, pp. 5492–5499, 2016. View at Publisher · View at Google Scholar · View at Scopus
  55. M. He and J. Wang, “Decreased serum brain-derived neurotrophic factor in Chinese patients with type 2 diabetes mellitus,” Acta Biochimica et Biophysica Sinica Shanghai, vol. 46, no. 5, pp. 426-427, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. F. Zhen, J. Zhang, X. Y. Liu et al., “Low BDNF is associated with cognitive deficits in patients with type 2 diabetes,” Psychopharmacology, vol. 227, no. 1, pp. 93–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Passaro, E. Dalla Nora, M. L. Morieri et al., “Brain-derived neurotrophic factor plasma levels: relationship with dementia and diabetes in the elderly population,” The Journals of Gerontology Series A, Biological Sciences and Medical Sciences, vol. 70, no. 3, pp. 294–302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Fujinami, K. Ohta, H. Obayashi et al., “Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: relationship to glucose metabolism and biomarkers of insulin resistance,” Clinical Biochemistry, vol. 41, no. 10-11, pp. 812–817, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Yi, X. Bao, X. Tang, X. Fan, and H. Xu, “Estrogen modulation of calretinin and BDNF expression in midbrain dopaminergic neurons of ovariectomised mice,” Journal of Chemical Neuroanatomy, vol. 77, pp. 60–67, 2016. View at Publisher · View at Google Scholar · View at Scopus
  60. C. C. Aguirre and M. Baudry, “Progesterone reverses 17beta-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices,” European Journal of Neuroscience, vol. 29, pp. 447–454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Singh, E. Meyer, and J. Simpkins, “The effect of ovariectomy and estradiol replacement on brain derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats,” Endocrinology, vol. 136, pp. 2320–2324, 1995. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Sohrabji, R. Miranda, and C. Toran-Allerand, “Identification of a putative estrogen response element in the gene coding for BDNF,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, pp. 11110–11114, 1995. View at Google Scholar
  63. T. Numakawa, M. Richards, S. Nakajima et al., “The role of brain-derived neurotrophic factor in comorbid depression: possible linkage with steroid hormones, cytokines, and nutrition,” Frontiers in Psychiatry, vol. 5, p. 136, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Comitato, A. Saba, A. Turrini, C. Arganini, and F. Virgili, “Sex hormones and macronutrient metabolism,” Critical Reviews in Food Science and Nutrition, vol. 55, no. 2, pp. 227–241, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. D. L. Eizirik and T. Mandrup-Poulsen, “A choice of death: the signal-transduction of immune-mediated beta-cell apoptosis,” Diabetologia, vol. 44, no. 12, pp. 2115–2133, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Spranger, A. Kroke, M. Möhlig et al., “Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam study,” Diabetes, vol. 52, no. 3, pp. 812–817, 2003. View at Google Scholar
  68. A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker, “C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus,” The Journal of the American Medical Association, vol. 286, pp. 327–334, 2001. View at Google Scholar
  69. D. Cai, M. Yuan, D. F. Frantz et al., “Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB,” Nature Medicine, vol. 11, no. 2, pp. 183–190, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. V. Mohamed-Ali, S. Goodrick, A. Rawesh et al., “Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, pp. 4196–4200, 1997. View at Publisher · View at Google Scholar
  71. F. B. Hu, J. B. Meigs, T. Y. Li, N. Rifai, and J. E. Manson, “Inflammatory markers and risk of developing type 2 diabetes in women,” Diabetes, vol. 53, pp. 693–700, 2004. View at Google Scholar
  72. K. Wallenius, J. O. Jansson, and V. Wallenius, “The therapeutic potential of interleukin-6 in treating obesity,” Expert Opinion on Biological Therapy, vol. 3, pp. 1061–1070, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. O. P. Kristiansen and T. Mandrup-Poulsen, “Interleukin-6 and diabetes: the good, the bad, or the indifferent?” Diabetes, vol. 54, Supplement 2, pp. 114–124, 2005. View at Google Scholar
  74. C. Tsigos, D. A. Papanicolaou, R. Defensor, C. S. Mitsiadis, I. Kyrou, and G. P. Chrousos, “Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure,” Neuroendocrinology, vol. 66, no. 1, pp. 54–62, 1997. View at Google Scholar
  75. V. Wallenius, K. Wallenius, B. Ahrén et al., “Interleukin-6-deficient mice develop mature-onset obesity,” Nature Medicine, vol. 8, pp. 75–79, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Stenlöf, I. Wernstedt, T. Fjällman, V. Wallenius, K. Wallenius, and J. O. Jansson, “Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 9, pp. 4379–4383, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Dicou, C. Masson, W. Jabbour, and V. Nerriere, “Increased frequency of NGF in sera of rheumatoid arthritis and systemic lupus erythematosus patients,” Neuroreport, vol. 5, no. 3, pp. 321–324, 1993. View at Google Scholar
  78. S. Bonini, A. Lambiase, F. Angelucci, L. Magrini, L. Manni, and L. Aloe, “Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 20, pp. 10955–10960, 1996. View at Google Scholar
  79. A. K. Patanella, M. Zinno, D. Quaranta et al., “Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients,” Journal of Neuroscience Research, vol. 88, no. 5, pp. 1106–1112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. S. J. Shin, H. E. Yoon, S. Chung, Y. G. Kim, and D. J. Kim, “Plasma brain-derived neurotrophic factor in hemodialysis patients,” International Journal of Medical Sciences, vol. 9, no. 9, pp. 772–777, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Patas, B. W. Penninx, B. A. Bus et al., “Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features,” Brain, Behavior, and Immunity, vol. 36, pp. 71–79, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. O. Schulte-Herbrüggen, C. Nassenstein, M. Lommatzsch, D. Quarcoo, H. Renz, and A. Braun, “Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes,” Journal of Neuroimmunology, vol. 160, pp. 204–209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. C. J. Huang, D. C. Mari, M. Whitehurst, A. Slusher, A. Wilson, and Y. Shibata, “Brain-derived neurotrophic factor expression ex vivo in obesity,” Physiology & Behavior, vol. 123, pp. 76–79, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. F. B. Pliego-Rivero, N. Bayatti, X. Giannakoulopoulos et al., “Brain-derived neurotrophic factor in human platelets,” Biochemical Pharmacology, vol. 54, no. 1, pp. 207–209, 1997. View at Google Scholar
  85. P. Stoll, A. Plessow, K. Bratke, J. C. Virchow, and M. Lommatzsch, “Differential effect of clopidogrel and aspirin on the release of BDNF from platelets,” Journal of Neuroimmunology, vol. 238, no. 1-2, pp. 104–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. N. Yazbek, A. Bapat, and N. Kleiman, “Platelet abnormalities in diabetes mellitus,” Coronary Artery Disease, vol. 14, pp. 365–371, 2003. View at Publisher · View at Google Scholar
  87. E. Coban, G. Yazicioglu, and M. Ozdogan, “Platelet activation in subjects with subclinical hypothyroidism,” Medical Science Monitor, vol. 13, no. 4, pp. CR211–CC214, 2007. View at Google Scholar
  88. J. L. Ferreiro, J. A. Gomez-Hospital, and D. J. Angiolillo, “Platelet abnormalities in diabetes mellitus,” Diabetes & Vascular Disease Research, vol. 7, pp. 251–259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Marx, A. Imhof, J. Froehlich et al., “Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease,” Circulation, vol. 107, pp. 1954–1957, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Gokulakrishnan, R. Deepa, V. Mohan, and M. D. Gross, “Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome: the Chennai urban rural epidemiology study,” Metabolism, vol. 55, pp. 237–242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. L. Lorgis, S. Amoureux, E. de Maistre et al., “Serum brain-derived neurotrophic factor and platelet activation evaluated by soluble P-selectin and soluble CD-40-ligand in patients with acute myocardial infarction,” Fundamental & Clinical Pharmacology, vol. 24, no. 4, pp. 525–530, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Kakouros, J. J. Rade, A. Kourliouros, and J. R. Resar, “Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective,” International Journal of Endocrinology, vol. 2011, Article ID 742719, 14 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. D. J. Schneider, R. M. Hardison, N. Lopes, B. E. Sobel, and M. M. Brooks, “Pro-thrombosis ancillary study group. Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (bypass angioplasty revascularization investigation 2 diabetes) substudy,” Diabetes Care, vol. 32, no. 5, pp. 944–949, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. H. S. Lim, A. D. Blann, and G. Y. Lip, “Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention,” Circulation, vol. 109, no. 21, pp. 2524–2528, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. H. Neubauer, P. Setiadi, B. Günesdogan, A. Pinto, J. Börgel, and A. Mügge, “Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in type 2 diabetes,” Diabetic Medicine, vol. 27, no. 4, pp. 384–390, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Furukawa, I. Fuse, Y. Iwakura et al., “Advanced glycation end products induce brain-derived neurotrophic factor release from human platelets through the Src-family kinase activation,” Cardiovascular Diabetology, vol. 16, no. 1, p. 20, 2017. View at Publisher · View at Google Scholar
  97. R. F. Mapanga and M. F. Essop, “Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways,” American Journal of Physiology Heart and Circulatory Physiology, vol. 310, no. 2, pp. H153–H173, 2016. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. Matsuzawa, T. Funahashi, and T. Nakamura, “Molecular mechanism of metabolic syndrome X: contribution of adipocytokines, adipocyte-derived bioactive substances,” Annals of the New York Academy of Sciences, vol. 892, pp. 146–154, 1999. View at Google Scholar
  99. N. Rasouli and P. A. Kern, “Adipocytokines and the metabolic complications of obesity,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, Supplement 1, no. 11, pp. S64–S73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Kapłon-Cieślicka, M. Postuła, M. Rosiak et al., “Association of adipokines and inflammatory markers with lipid control in type 2 diabetes,” Polish Archives of Internal Medicine, vol. 125, no. 6, pp. 414–423, 2015. View at Google Scholar
  101. I. S. Farooqi and S. O’Rahilly, “Leptin: a pivotal regulator of human energy homeostasis,” The American Journal of Clinical Nutrition, vol. 89, pp. 980S–984S, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. T. Komori, Y. Morikawa, K. Nanjo, and E. Senba, “Induction of brain-derived neurotrophic factor by leptin in the ventromedial hypothalamus,” Neuroscience, vol. 139, pp. 1107–1115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Ono, J. Ichihara, T. Nonomura et al., “Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice,” Biochemical and Biophysical Research Communications, vol. 238, pp. 633–637, 1997. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Tsuchida, T. Nonomura, M. Ono-Kishino, T. Nakagawa, M. Taiji, and H. Noguchi, “Acute effects of brain-derived neurotrophic factor on energy expenditure in obese diabetic mice,” International Journal of Obesity and Related Metabolic Disorders, vol. 25, pp. 1286–1293, 2001. View at Publisher · View at Google Scholar · View at Scopus
  105. F. Maekawa, K. Fujiwara, M. Toriya et al., “Brain-derived neurotrophic factor in VMH as the causal factor for and therapeutic tool to treat visceral adiposity and hyperleptinemia in type 2 diabetic Goto-Kakizaki rats,” Frontiers in Synaptic Neuroscience, vol. 5, p. 7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Nakagawa, Y. Ogawa, K. Ebihara et al., “Anti-obesity and anti-diabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance,” International Journal of Obesity and Related Metabolic Disorders, vol. 27, no. 5, pp. 557–565, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Ehrlich, H. Salbach-Andrae, S. Eckart et al., “Serum brain-derived neurotrophic factor and peripheral indicators of the serotonin system in underweight and weight-recovered adolescent girls and women with anorexia nervosa,” Journal of Psychiatry & Neuroscience, vol. 34, no. 4, pp. 323–329, 2009. View at Google Scholar
  108. E. Golden, A. Emiliano, S. Maudsley et al., “Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore longitudinal study of aging,” PLoS One, vol. 5, no. 4, article e10099, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. C. L. Roth, C. Elfers, U. Gebhardt, H. L. Müller, and T. Reinehr, “Brain-derived neurotrophic factor and its relation to leptin in obese children before and after weight loss,” Metabolism, vol. 62, no. 2, pp. 226–234, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. M. G. Hohenadel, M. S. Thearle, B. A. Grice et al., “Brain-derived neurotrophic factor in human subjects with function-altering melanocortin-4 receptor variants,” International Journal of Obesity (London), vol. 38, no. 8, pp. 1068–1074, 2014. View at Publisher · View at Google Scholar · View at Scopus
  111. M. G. Hristova, “Metabolic syndrome and neurotrophins: effects of metformin and non-steroidal antiinflammatory drug treatment,” The Eurasian Journal of Medicine, vol. 43, no. 3, pp. 141–145, 2011. View at Publisher · View at Google Scholar
  112. D. Y. Yoo, W. Kim, S. M. Nam et al., “Reduced cell proliferation and neuroblast differentiation in the dentate gyrus of high fat diet-fed mice are ameliorated by metformin and glimepiride treatment,” Neurochemical Research, vol. 36, no. 12, pp. 2401–2408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. S. P. Patil, P. D. Jain, P. J. Ghumatkar, R. Tambe, and S. Sathaye, “Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice,” Neuroscience, vol. 277, pp. 747–754, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. J. S. Allard, E. J. Perez, K. Fukui, P. Carpenter, D. K. Ingram, and R. de Cabo, “Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice,” Behavioural Brain Research, vol. 301, pp. 1–9, 2016. View at Publisher · View at Google Scholar · View at Scopus
  115. J. Ma, J. Liu, H. Yu, Y. Chen, Q. Wang, and L. Xiang, “Effect of metformin on Schwann cells under hypoxia condition,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 6, pp. 6748–6755, 2015. View at Google Scholar
  116. D. Sola, L. Rossi, G. P. Schianca et al., “Sulfonylureas and their use in clinical practice,” Archives of Medical Science, vol. 11, no. 4, pp. 840–848, 2015. View at Google Scholar
  117. L. Gong, S. Goswami, K. M. Giacomini, R. B. Altman, and T. E. Klein, “Metformin pathways: pharmacokinetics and pharmacodynamics,” Pharmacogenetics and Genomics, vol. 22, no. 11, pp. 820–827, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Rosiak, M. Postula, A. Kaplon-Cieslicka et al., “Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes,” Advances in Medical Sciences, vol. 58, no. 2, pp. 362–368, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. I. J. Riphagen, S. J. Logtenberg, K. H. Groenier et al., “Is the association of serum sodium with mortality in patients with type 2 diabetes explained by copeptin or NT-proBNP? (ZODIAC-46),” Atherosclerosis, vol. 242, no. 1, pp. 179–185, 2015. View at Publisher · View at Google Scholar · View at Scopus
  120. W. W. Winder and D. G. Hardie, “AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes,” American Journal of Physiology, vol. 277, 1, Part 1, pp. E1–E10, 1999. View at Google Scholar
  121. U. L. Aune, L. Ruiz, and S. Kajimura, “Isolation and differentiation of stromal vascular cells to beige/brite cells,” Journal of Visualized Experiments, no. 73, article e50191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. Y. Li, K. Wong, K. Walsh, B. Gao, and M. W. Zang, “Retinoic acid receptor beta stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body diabetes page 44 of 51 energy homeostasis in mice,” Journal of Biological Chemistry, vol. 288, pp. 10490–10504, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. Y. Li, K. Wong, A. Giles et al., “Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21,” Gastroenterology, vol. 146, pp. 539–549.e7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. Q. A. Wang, P. E. Scherer, and R. K. Gupta, “Improved methodologies for the study of adipose biology: insights gained and opportunities ahead,” The Journal of Lipid Research, vol. 55, pp. 605–624, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Zang, S. Xu, K. A. Maitland-Toolan et al., “Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice,” Diabetes, vol. 55, pp. 2180–2191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  126. B. J. Stith, M. L. Goalstone, R. Espinoza, C. Mossel, D. Roberts, and N. Wiernsperger, “The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes,” Endocrinology, vol. 137, pp. 2990–2999, 1996. View at Publisher · View at Google Scholar
  127. R. F. Santos, R. Nomizo, A. Bopsco, B. L. Wajchenberg, G. M. Reaven, and S. Azhar, “Effect of metformin on insulin-stimulated tyrosine kinase activity of erythrocytes from obese women with normal glucose tolerance,” Diabetes & Metabolism, vol. 23, pp. 143–148, 1997. View at Google Scholar
  128. B. J. Stith, K. Woronoff, and N. Wiernsperger, “Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin,” Biochemical Pharmacology, vol. 55, pp. 533–536, 1998. View at Google Scholar
  129. S. J. Tsai, “Peripheral administration of brain-derived neurotrophic factor to Rett syndrome animal model: a possible approach for the treatment of Rett syndrome,” Medical Science Monitor, vol. 18, no. 8, pp. HY33–HY36, 2012. View at Google Scholar
  130. BDNF Study Group, “A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF study group (phase III),” Neurology, vol. 52, pp. 1427–1433, 1999. View at Google Scholar
  131. C. Géral, A. Angelova, and S. Lesieur, “From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF),” Pharmaceutics, vol. 5, no. 1, pp. 127–167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  132. J. H. Kordower, S. Palfi, E. Y. Chen et al., “Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease,” Annals of Neurology, vol. 46, no. 3, pp. 419–424, 1999. View at Google Scholar
  133. L. Li, T. Yu, L. Yu, H. Li, Y. Liu, and D. Wang, “Exogenous brain-derived neurotrophic factor relieves pain symptoms of diabetic rats by reducing excitability of dorsal root ganglion neurons,” International Journal of Neuroscience, vol. 126, no. 8, pp. 749–758, 2016. View at Publisher · View at Google Scholar · View at Scopus
  134. C. Morgado, P. Pereira-Terra, C. D. Cruz, and I. Tavares, “Minocycline completely reverses mechanical hyperalgesia in diabetic rats through microglia-induced changes in the expression of the potassium chloride co-transporter 2 (KCC2) at the spinal cord,” Diabetes, Obesity and Metabolism, vol. 13, no. 2, pp. 150–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Seki, T. Tanaka, H. Nawa et al., “Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells,” Diabetes, vol. 53, no. 9, pp. 2412–2419, 2004. View at Google Scholar
  136. L. R. Zheng, Y. Y. Zhang, J. Han et al., “Nerve growth factor rescues diabetic mice heart after ischemia/reperfusion injury via up-regulation of the TRPV1 receptor,” Journal of Diabetes and its Complications, vol. 29, no. 3, pp. 323–328, 2015. View at Publisher · View at Google Scholar · View at Scopus
  137. W. M. Walwyn, Y. Matsuka, D. Arai et al., “HSV-1-mediated NGF delivery delays nociceptive deficits in a genetic model of diabetic neuropathy,” Experimental Neurology, vol. 198, pp. 260–270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  138. W. E. Lyons, L. A. Mamounas, G. A. Ricaurte et al., “Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, pp. 15239–15244, 1999. View at Google Scholar
  139. S. G. Kernie, D. J. Liebl, and L. F. Parada, “BDNF regulates eating behavior and locomotor activity in mice,” The EMBO Journal, vol. 19, pp. 1290–1300, 2000. View at Publisher · View at Google Scholar
  140. M. Rios, G. Fan, C. Fekete et al., “Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity,” Molecular Endocrinology, vol. 15, pp. 1748–1757, 2001. View at Publisher · View at Google Scholar
  141. M. Yamanaka, Y. Itakura, A. Tsuchida, T. Nakagawa, H. Noguchi, and M. Taiji, “Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice,” Diabetes, Obesity and Metabolism, vol. 9, no. 6, pp. 879–888, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. F. Bretzner, J. Liu, E. Currie, A. J. Roskams, and W. Tetzlaff, “Undesired effects of a combinatorial treatment for spinal cord injury--transplantation of olfactory ensheathing cells and BDNF infusion to the red nucleus,” European Journal of Neuroscience, vol. 28, no. 9, pp. 1795–1807, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. R. N. Pearse, S. L. Swendeman, Y. Li, D. Rafii, and B. L. Hempstead, “A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival,” Blood, vol. 105, no. 11, pp. 4429–4436, 2005. View at Publisher · View at Google Scholar · View at Scopus
  144. E. Vanhecke, E. Adriaenssens, S. Verbeke et al., “Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival,” Clinical Cancer Research, vol. 17, no. 7, pp. 1741–1752, 2011. View at Publisher · View at Google Scholar · View at Scopus